Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Trial Profile

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 01 Targovax (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Targovax
  • Most Recent Events

    • 23 May 2019 According to a Targovax ASA media release, this three-year survival data finalizes the data collection and the trial is now considered complete. The completed data will be presented and published later this year.
    • 23 May 2019 Results assessing median overall survival and three-year survival rate published in the Targovax ASA Media Release
    • 14 Feb 2019 According to a Targovax ASA media release, 3 year survival data from the trial is expected in 1H 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top